Probi completed the first commercial production batches of Blis K12 at its U.S. manufacturing site. The company was able to eliminate the need for dairy milk products in the formulation as well.
Probi (Lund, Sweden) completed the first commercial production batches of a dairy-free Streptococcus salivarius called Blis K12 at its U.S. manufacturing site. The new Blis strains support the natural immune defense and help reduce the risk of mouth and throat infections. Since its partnership with New Zealand-based Blis Technologies Ltd., Probi now manufactures Blis strains at its fermentation facility in Redmond, WA. The new strains will shortly be offered to Probi customers worldwide.
“The technology transfer of Blis strains to Probi has gone smoothly and we have been able to make very rapid progress due to our sizable investments in fermentation technology and upgrades to our analytical capability,” said Steve Preston, Probi’s head of fermentation, in a press release. “Furthermore, as part of our high throughput screening program for culture media optimization, we have been able to completely eliminate the need for dairy (milk) products in the formulation. We believe this is very helpful for customers seeking to produce allergen free probiotic products.”
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.